Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Sell
17
GLUE Quote, Financials, Valuation and Earnings
Last price:
$7.05
Seasonality move
:
-3.94%
Day range:
$6.86 - $7.35
52-week range:
$3.21 - $12.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.16x
Volume:
728.3K
Avg. volume:
1.5M
1-year change:
28.47%
Market cap:
$443.6M
Revenue:
--
EPS (TTM):
-$1.83
Analysts' Opinion
-
Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.00, Monte Rosa Therapeutics has an estimated upside of 121.61% from its current price of $7.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing -52.36% downside risk from its current price of $7.22.
Fair Value
-
According to the consensus of 6 analysts, Monte Rosa Therapeutics has 121.61% upside to fair value with a price target of $16.00 per share.
GLUE vs. S&P 500
-
Over the past 5 trading days, Monte Rosa Therapeutics has overperformed the S&P 500 by 0.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Monte Rosa Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Monte Rosa Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Monte Rosa Therapeutics reported revenues of $9.2M.
Earnings Growth
-
Monte Rosa Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Monte Rosa Therapeutics reported earnings per share of -$0.29.
Enterprise value:
201.4M
EV / Invested capital:
0.98x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-287.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $9.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$103.3M | -$140.9M | -$129M | -$37M | -$26.5M | |
| EBITDA | -$99.8M | -$135.5M | -$121.1M | -$35.1M | -$24.4M | |
| Diluted EPS | -$2.16 | -$2.69 | -$1.83 | -$0.70 | -$0.29 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $370.5M | $295.2M | $182.9M | $251.2M | |
| Total Assets | -- | $384M | $357.6M | $252.1M | $315.1M | |
| Current Liabilities | -- | $12.7M | $21.8M | $22.6M | $41.6M | |
| Total Liabilities | -- | $14.7M | $66.5M | $67.6M | $109.6M | |
| Total Equity | -- | $369.3M | $291.1M | $184.5M | $205.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$82.7M | -$97.4M | -$57.3M | -$24.7M | -$21M | |
| Cash From Investing | -$168.3M | $20.6M | $741K | $35.6M | $37.7M | |
| Cash From Financing | -$103K | $22.8M | $123.5M | $1.1M | $15K | |
| Free Cash Flow | -$91.4M | -$122M | -$62.8M | -$26.4M | -$21.4M | |
GLUE
Sector
Market Cap
$443.6M
$46.5M
Price % of 52-Week High
58.23%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
28.47%
-31.38%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$7.15
200-day SMA
Buy
Level
$5.94
Bollinger Bands (100)
Buy
Level
4.97 - 8.55
Chaikin Money Flow
Sell
Level
-14.6M
20-day SMA
Sell
Level
$8.39
Relative Strength Index (RSI14)
Sell
Level
42.86
ADX Line
Sell
Level
11.88
Williams %R
Neutral
Level
-76.4317
50-day SMA
Sell
Level
$8.07
MACD (12, 26)
Sell
Level
-0.40
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
70.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Stock Forecast FAQ
In the current month, GLUE has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The GLUE average analyst price target in the past 3 months is $16.00.
-
Where Will Monte Rosa Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Monte Rosa Therapeutics share price will rise to $16.00 per share over the next 12 months.
-
What Do Analysts Say About Monte Rosa Therapeutics?
Analysts are divided on their view about Monte Rosa Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Monte Rosa Therapeutics is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Monte Rosa Therapeutics's Price Target?
The price target for Monte Rosa Therapeutics over the next 1-year time period is forecast to be $16.00 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is GLUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Monte Rosa Therapeutics is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GLUE?
You can purchase shares of Monte Rosa Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Monte Rosa Therapeutics shares.
-
What Is The Monte Rosa Therapeutics Share Price Today?
Monte Rosa Therapeutics was last trading at $7.05 per share. This represents the most recent stock quote for Monte Rosa Therapeutics. Yesterday, Monte Rosa Therapeutics closed at $7.22 per share.
-
How To Buy Monte Rosa Therapeutics Stock Online?
In order to purchase Monte Rosa Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 3.22% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 4.72% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.82% over the past day.
